Clinical Trials Logo

Solid Neoplasm clinical trials

View clinical trials related to Solid Neoplasm.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03804255 Withdrawn - Melanoma Clinical Trials

Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting

Start date: January 8, 2019
Phase:
Study type: Observational

This trial assesses current biomarker testing practices for common solid cancers in precision oncology in the community setting. Cancer biomarkers are used for diagnosing the disease, determining prognosis, predicting response to a targeted therapy, or monitoring response to therapy. Testing quality, including accuracy and timeliness, is imperative for correct disease prognosis and identification of patients who may or may not benefit from a targeted therapy. Assessing current biomarker testing practices may help doctors identify gaps and variations in testing as well as on potential ?best practices? that may be informative and generalizable to community oncology programs.

NCT ID: NCT02567396 Withdrawn - Clinical trials for Head and Neck Squamous Cell Carcinoma

Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Start date: June 2016
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of talazoparib in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or have spread to other places in the body (metastatic) and cannot be removed by surgery and liver or kidney dysfunction. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.